Lorcaserin

Results: 29



#Item
12014 ANNUAL REPORT  Focus G Protein-Coupled Receptors Technologies and Expertise

2014 ANNUAL REPORT Focus G Protein-Coupled Receptors Technologies and Expertise

Add to Reading List

Source URL: www.arenapharm.com

Language: English - Date: 2015-04-24 15:12:10
2Contains Nonbinding Recommendations  Draft Guidance on Lorcaserin Hydrochloride This draft guidance, once finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does n

Contains Nonbinding Recommendations Draft Guidance on Lorcaserin Hydrochloride This draft guidance, once finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does n

Add to Reading List

Source URL: www.fda.gov

Language: English
3Microsoft Word - Final Summary Minutes EMDAC[removed]doc

Microsoft Word - Final Summary Minutes EMDAC[removed]doc

Add to Reading List

Source URL: www.fda.gov

Language: English
4California Food Recall Information Recall Name Bethel Nutritional Consulting, Inc. Recalls B-Lipo Capsules Due to Undeclared Drug Ingredient - Lorcaserin Recall

California Food Recall Information Recall Name Bethel Nutritional Consulting, Inc. Recalls B-Lipo Capsules Due to Undeclared Drug Ingredient - Lorcaserin Recall

Add to Reading List

Source URL: www.cdph.ca.gov

- Date: 2015-01-13 19:00:43
    5HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BELVIQ safely and effectively. See full prescribing information for BELVIQ.  • C

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BELVIQ safely and effectively. See full prescribing information for BELVIQ. • C

    Add to Reading List

    Source URL: www.belviq.com

    Language: English - Date: 2014-11-19 10:33:00
    6HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BELVIQ safely and effectively. See full prescribing information for BELVIQ.  • C

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BELVIQ safely and effectively. See full prescribing information for BELVIQ. • C

    Add to Reading List

    Source URL: www.belviq.com

    Language: English - Date: 2014-11-19 10:33:00
    7Kansas Medical Assistance Program  P O Box 3571 Topeka, KS[removed]Provider[removed]Beneficiary[removed]

    Kansas Medical Assistance Program P O Box 3571 Topeka, KS[removed]Provider[removed]Beneficiary[removed]

    Add to Reading List

    Source URL: www.kdheks.gov

    Language: English - Date: 2014-09-05 14:11:16
    8U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

    U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

    Add to Reading List

    Source URL: www.fda.gov

    Language: English
    9U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

    U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

    Add to Reading List

    Source URL: www.fda.gov

    Language: English
    10Page 2  The magnitude of personal financial interest: $0 – $5,000 per year Description of the Particular Matter to Which the Waiver Applies: The committee will discuss the safety and efficacy of new drug application (

    Page 2 The magnitude of personal financial interest: $0 – $5,000 per year Description of the Particular Matter to Which the Waiver Applies: The committee will discuss the safety and efficacy of new drug application (

    Add to Reading List

    Source URL: www.fda.gov

    Language: English